What criminal charges were brought?
The DOJ prosecuted seven generic companies — Sandoz paid $195M, Teva $225M under a 2023 deferred prosecution, Glenmark $30M — with consumers likely overcharged by at least $350 million on the conspiracies charged against Teva alone.
The Justice Department's Antitrust Division pursued criminal prosecutions against seven generic pharmaceutical companies accused of conspiring to fix prices, rig bids and allocate markets. In March 2020 Sandoz, then part of Novartis, agreed to a $195 million criminal penalty. Teva was indicted in August 2020 and, after three years of litigation, entered a deferred prosecution agreement in August 2023 with a $225 million penalty, admitting conspiracies involving pravastatin, clotrimazole and tobramycin. Glenmark paid $30 million over pravastatin, and the DOJ had alleged Glenmark and others raked in $200 million from the pravastatin scheme alone. Teva was also accused of conspiring with Taro and with Sandoz on other drugs. The Justice Department described consumers as likely overcharged by at least $350 million in the conspiracies charged against Teva.